Sapphire Biotech
Click the link below to learn about the latest research using
Sapphire’s Rapid Diagnostic Test.
Our mission
Our mission is to improve global cancer care through the development of novel Therapeutics for inhibiting metastatic cancer growth, Diagnostic for early cancer detection, response to treatment, and recurrence monitoring.
Early Cancer Detection
QSOX1, a unique enzyme elevated in cancer patients can be detected earlier than circulating tumor cells.
Response to Treatment
Sapphire Biotech’s lead compound has shown to significantly reduce tumors in under 20 days.
Innovative Research
Sapphire’s expert scientists are commited to development of novel diagnostic for early detection and treatment.
Dedicated to Changing Lives Through Research
Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The company’s development of QSOX1 as a unique cancer biomarker has led it to important discoveries based on testing hundreds of human samples. Sapphire’s lead compound has been tested in animal studies has shown to significantly reduce tumors by two-thirds in under 20 days.
Global Demand and Growing Market Potential
With the oversight and expertise of internationally-recognized scientists and medical experts, Sapphire Biotech not only has great potential to help hundreds of millions of cancer patients throughout the U.S., but also become a strategic asset for its investors. The global cancer therapy market is experiencing a strong growth pattern with a CAGR over the next four years of 8.37% and 90% of cancer patients dying from metastatic cancer. Sapphire’s team has developed never-before-seen and proven compounds to combat metastatic cancer.
$136.2 Billion
2018 Global Cancer Therapy Market Value
$220.7 Billion
Estimated Global Cancer Therapy Market Value by 2024
90%
Of cancer deaths are caused by metastatic cancer
About Our Founder
Catalina Valencia, J.D.
Chief Executive Officer
Catalina Valencia, J.D. is the Chief Executive Officer of Sapphire Biotech. She is a results-oriented entrepreneur that specializes in leading businesses to success through the strategic development of businesses and products, management of intellectual property portfolios and structuring and negotiation of complex transactions, including license deals. Valencia brings extensive management experience with biotechnology startups to the Sapphire Biotech team, including her leadership of early-stage Genentech.
Reach Us
Sapphire Biotech, Inc.
San Diego, CA 92121
info@sapphirebiotech.com